AGP Picks
View all

Health Subcommittee Chairwoman Dr. Miller-Meeks Leads Oversight Hearing to Examine Future of Psychedelic-Assisted Treatments for Veterans

News originally published by

U.S. House Committee on Veterans' Affairs

Today, Rep. Mariannette Miller-Meeks (R-Iowa), the Chairwoman of the House Committee on Veterans’ Affairs Subcommittee on Health delivered the following opening remarks, as prepared, at the start the subcommittee’s oversight hearing to look into the Department of Veterans Affairs’ (VA) research into psychedelic-assisted therapies and the role they could play in addressing PTSD, depression, substance abuse disorders, and other health conditions facing veterans.

 

Good afternoon.

 

This oversight hearing of the Subcommittee on Health will now come to order.

 

Without objection, the Chair may declare a recess at any time.

 

I would like to welcome our Members and witnesses to today's hearing on psychedelic-assisted therapies for veterans.

 

Before we discuss the promise of these emerging therapies, I think it is important to recognize the challenges we are trying to address.


According to VA's latest National Veteran Suicide Prevention Annual Report, an average of 17 veterans died by suicide every single day in 2024.


That is more than 6,400 veterans in a single year.


And despite years of congressional attention, significant federal investments, and countless suicide prevention initiatives, those numbers have remained somewhat stagnant. 

 

That should trouble every Member of this Committee.

 

As a physician and a 24-year Army veteran, I know that the wounds of military service are not always visible.

 

For many veterans, the effects of post-traumatic stress disorder, depression, and substance use disorders persist long after their military service has ended.


While there have been numerous advancements in research and mental healthcare, far too many veterans continue to struggle to find treatments that work for them.


We cannot accept these outcomes as inevitable.


Something needs to change.


We must continue supporting the treatments and programs that work, while recognizing that conventional approaches do not always provide relief for every veteran.


And if there are emerging therapies that could improve veterans' mental health, reduce suffering, and potentially save lives, then we have a responsibility to at least explore them at the federal level.


That is why I am proud to be leading today's hearing on psychedelic-assisted therapies for veterans.

 

As a physician, I understand the importance of ensuring that new treatments are supported by credible scientific evidence and appropriate safeguards.

 

But medical innovation also requires a willingness to explore new approaches to care.

 

Emerging research into substances such as MDMA and psilocybin has shown promise for treating PTSD, treatment-resistant depression, and other serious mental health conditions.

 

And while more research is needed, these developments should give us all a reason to be optimistic.

 

Fortunately, VA is uniquely positioned to help lead this effort.

 

With one of the largest integrated healthcare systems in the country, a robust research enterprise, and decades of experience treating veterans with complex mental health conditions, VA has the capabilities to help move these therapies from research toward clinical practice.

 

I am encouraged by the progress we have already seen.

 

In 2024, VA announced funding for its first clinical trial examining MDMA-assisted therapy for veterans suffering from PTSD and alcohol use disorder.

 

Earlier this year, that research moved forward with a randomized clinical trial at VA facilities in Rhode Island and Connecticut.

 

VA has also launched the PIVOT trial, examining the safety and effectiveness of psilocybin for veterans suffering from treatment-resistant depression.

 

I also want to recognize Secretary Collins and the Trump administration for the steps taken to further advance this forward-thinking research.


In April of this year, the Trump administration issued an Executive Order directing greater federal coordination to accelerate the development of treatments for serious mental illness.


Following that Executive Order, VA entered into agreements with the Department of Health and Human Services and the Food and Drug Administration to strengthen research collaboration, improve information sharing, support workforce training, and prepare for the potential clinical deployment of these therapies.


The Trump administration has also taken steps to accelerate the regulatory review of promising treatments through FDA's existing expedited development and review pathways.

 

These are meaningful developments, and I appreciate Secretary Collins' commitment to advancing innovative, evidence-based treatments for veterans.

 

 But today's hearing is also about what comes next.

 

Because some of these emerging therapies are already in advanced stages of clinical development, and there is a real possibility that certain treatments could receive FDA approval within the next year.

 

 That raises an important question.

 

Will VA be ready?

 

Will VA have the trained clinicians, appropriate facilities, and clinical protocols necessary to safely administer these treatments?

 

How quickly could approved therapies become available to eligible veterans?

 

And how will VA ensure that access to these treatments is not determined by where a veteran happens to live?

 

These are questions we should be answering now.

 

Preparing for the next generation of mental health care cannot begin the day a treatment receives FDA approval.

 

And while FDA approval is a critical milestone, it is only one part of the process.

 

Many of these substances remain subject to strict federal controlled-substance requirements.

 

Additional coordination with the Drug Enforcement Administration and the Department of Justice may be necessary to address scheduling, registration, handling, and distribution requirements.

 

VA, HHS, FDA, DEA, and DOJ must work together to ensure that each agency understands its responsibilities and that unnecessary regulatory delays do not prevent veterans from accessing safe and effective treatments.

 

We must also consider how these therapies would fit into VA's broader healthcare delivery system.

 

VA may not have the specialized workforce or facilities to provide these treatments at every medical center.

 

That is why we should examine the potential role of qualified community providers in expanding access while maintaining appropriate clinical oversight.

 

Congress also has an important role to play.


We need to understand whether VA has the authorities, resources, and flexibility necessary to prepare for these emerging treatments.


And we need to identify whether additional congressional action may be needed to support research, workforce development, and eventual implementation.


Today, I look forward to hearing from our witnesses about the current state of psychedelic-assisted therapies, what we have learned from the research conducted so far, and what challenges remain.


I hope to better understand what the future of these treatments could look like within VA, how prepared the federal government is for their potential approval, and how Congress can meaningfully support these efforts.


If these emerging therapies can help improve outcomes, restore hope, and save lives, then we owe it to our veterans to responsibly pursue that opportunity.

 

They have earned nothing less.

 

I now yield to Ranking Member Brownley for any opening remarks she may have.

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Healthcare Press Releases

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.